Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Income Statement
Earnings Waterfall
Shandong Xinhua Pharmaceutical Co Ltd
Revenue
|
7.9B
CNY
|
Cost of Revenue
|
-5.8B
CNY
|
Gross Profit
|
2.2B
CNY
|
Operating Expenses
|
-1.7B
CNY
|
Operating Income
|
503.3m
CNY
|
Other Expenses
|
-16.5m
CNY
|
Net Income
|
486.8m
CNY
|
Income Statement
Shandong Xinhua Pharmaceutical Co Ltd
Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue |
6 623
N/A
|
6 673
+1%
|
7 073
+6%
|
7 503
+6%
|
8 311
+11%
|
8 511
+2%
|
8 547
+0%
|
8 101
-5%
|
7 936
-2%
|
|
Gross Profit | ||||||||||
Cost of Revenue |
(4 926)
|
(5 046)
|
(5 329)
|
(5 509)
|
(6 037)
|
(6 129)
|
(6 134)
|
(5 773)
|
(5 762)
|
|
Gross Profit |
1 698
N/A
|
1 627
-4%
|
1 744
+7%
|
1 994
+14%
|
2 274
+14%
|
2 382
+5%
|
2 413
+1%
|
2 328
-4%
|
2 174
-7%
|
|
Operating Income | ||||||||||
Operating Expenses |
(1 224)
|
(1 202)
|
(1 311)
|
(1 498)
|
(1 724)
|
(1 800)
|
(1 822)
|
(1 788)
|
(1 670)
|
|
Selling, General & Administrative |
(907)
|
(899)
|
(980)
|
(1 085)
|
(1 330)
|
(1 354)
|
(1 360)
|
(1 300)
|
(1 195)
|
|
Research & Development |
(343)
|
(340)
|
(352)
|
(346)
|
(379)
|
(413)
|
(428)
|
(419)
|
(449)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
(92)
|
0
|
0
|
0
|
(91)
|
0
|
|
Other Operating Expenses |
26
|
36
|
22
|
26
|
(15)
|
(34)
|
(33)
|
23
|
(26)
|
|
Operating Income |
474
N/A
|
425
-10%
|
433
+2%
|
496
+15%
|
550
+11%
|
581
+6%
|
591
+2%
|
541
-9%
|
503
-7%
|
|
Pre-Tax Income | ||||||||||
Interest Income Expense |
(48)
|
(29)
|
(17)
|
(20)
|
(27)
|
(13)
|
(18)
|
(4)
|
7
|
|
Non-Reccuring Items |
3
|
4
|
4
|
(2)
|
6
|
4
|
12
|
(7)
|
9
|
|
Total Other Income |
(5)
|
(4)
|
(4)
|
(2)
|
(4)
|
(4)
|
(2)
|
3
|
(3)
|
|
Pre-Tax Income |
424
N/A
|
396
-7%
|
416
+5%
|
472
+13%
|
525
+11%
|
568
+8%
|
584
+3%
|
533
-9%
|
517
-3%
|
|
Net Income | ||||||||||
Tax Provision |
(58)
|
(45)
|
(48)
|
(46)
|
(54)
|
(65)
|
(60)
|
(27)
|
(19)
|
|
Income from Continuing Operations |
366
|
351
|
368
|
426
|
471
|
503
|
523
|
506
|
497
|
|
Income to Minority Interest |
(9)
|
(8)
|
(11)
|
(15)
|
(17)
|
(17)
|
(14)
|
(10)
|
(11)
|
|
Net Income (Common) |
357
N/A
|
343
-4%
|
357
+4%
|
411
+15%
|
454
+11%
|
487
+7%
|
510
+5%
|
497
-3%
|
487
-2%
|
|
EPS (Diluted) |
0.56
N/A
|
0.53
-5%
|
0.56
+6%
|
0.62
+11%
|
0.66
+6%
|
0.7
+6%
|
0.75
+7%
|
0.72
-4%
|
0.71
-1%
|